LinkedInFacebook
back to homepage

Session 13

The importance of toxicokinetics for human risk assessment

Programme of the Session

  • The importance of information on toxicokinetics for human health risk assessment - some examples 
    Liesbeth Geraets, Marco Zeilmaker, Peter Bos 
    RIVM, Bilthoven, Netherlands
  • Implementation of toxicokinetics in toxicity studies - example of 4-methylanisole 
    Petra van Kesteren, Esther Brandon, Aldert Piersma, Peter Bos
    RIVM, Bilthoven, Netherlands 
  • The application of toxicokinetics in an animal-free risk assessment 
    Eric Fabian, Christian Haase, Caroline Gomes, Barbara Birk, Tzutzuy Ramirez, Rene Zbranek, Bennard van Ravenzwaay, Robert Landsiedel 
    Experimental Toxicology and Ecology, BASF SE, 67056 Ludwigshafen, Germany
  • State-of-the-art of the assessment of ADME using multiple organs on a chip 
    Ilka Maschmeyer1, Alexandra Lorenz1, Sophie Bauer1, 2, Anja Ramme1, Thamée Rings3, Jochen Kuehnl3, Uwe Marx
    1TissUse GmbH, Berlin, Germany; 2Technische Universität Berlin, Berlin, Germany; 3Front End Innovation, Dept. Toxicology, Beiersdorf, Hamburg, Germany
  • Using a “Body-on-a-Chip” including toxicokinetics to predict human response to chemical and drug exposure 
    Michael Shuler 
    Department of Biomedical Engineering, Cornell University, Ithaca, United States; Hesperos, Inc., Orlando, United States

Session Abstract

Most of the current regulations do not require data on toxicokinetics for the risk assessment of chemicals, while there are clear examples of how the risk assessment would benefit from such information, e.g., for a better understanding of the dose-response relationship, of the mode of action, for interspecies extrapolation and/or for route-to-route extrapolation. Moreover, when transferring from animal testing to alternative methods, toxicokinetic information becomes more and more essential, e.g., to guide the design of in vitro toxicity tests (e.g., on exposure conditions) or to extrapolate in vitro concentration-response relationships to in vivo dose-response relationships. This symposium aims to show the advantage of toxicokinetic information for human health risk assessment. First, a general introduction will be given followed by a presentation on incorporation of toxicokinetics in in vivo repeated dose toxicity studies. The third presentation addresses the use of kinetics when moving towards toxicity testing based on alternatives to animal tests. The last two presentations aim to present important recent developments on how kinetic parameters can be collected and used based on the organ-on-chip technology. Organ-on-a-chip technology holds great promise for an integrated analysis of the toxicokinetics and toxicodynamics of chemicals without animal testing. 
 
EUROTOXSETOX

© 2016–2017 GUARANT International